Early Bird Ends Tomorrow

~ Next Phase Admin ~ Leave a comment

By Caitlin Dolegowski, Marketing Specialist, LSN

RESI Partnering Week, September 13-17 early bird rates end tomorrow! Register by August 6 to save $50 on standard, premier, and bundle packages. RESI Partnering Week is a five-day virtual partnering experience designed to connect early-stage life science and healthcare startups with investors and strategic partners that are a fit for their product and stage of development.

RESI Partnering Week is unique because it features three events (Digital RESI, RESI AI, and RESI Longevity) that each use a match-based partnering platform designed to take the guesswork out of partnering because it enables users to filter attendees to meet with based on their fundraising needs. To learn more about the partnering platform, join us for a free fundraising bootcamp August 11 or August 18.

Additionally, RESI Partnering Week features conversations with entrepreneurs and investors around specific topics related to the early-stage fundraising ecosystem through expert panels and hosts the Innovator’s Pitch Challenge (IPC), providing opportunities for fundraising executives to pitch directly to a panel of relevant, active investors. IPC applications are accepted on a first-come-first-serve basis, so apply by August 20 to be considered!

Whether sourcing elite technology assets or seeking funding from a strategic partner who is a fit for your company, RESI Partnering Week is a one-stop shop to help you meet your needs. Learn more about what each event has to offer and sign up by August 6 to save!

RPW September 2021 Confirmed Investors
Confirmed RESI Investors Confirmed RESI AI Investors Confirmed RESI Longevity Investors

As of August 5

Tech Hubs & RESI Partnering Week

~ Next Phase Admin ~ Leave a comment

By Elizabeth Murphy, Manager of Business Development, LSN

Life Science Nation (LSN) recognizes how Tech Hubs – global incubators and accelerators – are impact entrepreneurs for success, and in turn, close collaboration with these groups and their constituent companies add a value to partnering events, like RESI Partnering Week. Over the last year, LSN has hosted Tech Hubs such as AZ Bio, Women in Bio, and Lyonbiopole and their constituents have had the opportunity to meet the investors and strategic partners who are part of the RESI community. Get to know these Tech Hubs and check out the opportunities available to constituents of those participating in the RESI Partnering Week Global Tech Hub Gathering:

We are currently offering two programs to accelerate Tech Hub involvement and help fund constituents:

  • 50% discount on any RESI conference registration for early-stage constituent companies from participating Tech Hubs
  • Group Fundraising Package ($1,500 per company) for Tech Hubs including:
  • 3-month access to the Investor Database
  • Registration at RESI
  • Participation in the Innovator’s Pitch Challenge

The Arizona Bioindustry Association (AZBio)

AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona’s life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed. AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and MedTech community.

Lyonbiopole

As a Cluster, Lyonbiopole is the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region. It’s supporting ambitious projects and innovative companies in the healthcare and life sciences sectors. Its aim is to help innovators develop new technologies, products, and services in a push toward a more personalized medicine and better treatments for patients. Its four strategic areas include human medicine, veterinary medicine, in vitro diagnostics, and medical devices and medical technologies.

Women in Bio (WIB)

Women in Bio is an incubator of North American women in the life science industry. WIB aims to help women achieve the highest levels of leadership, influence and decision-making that they desire. As WIB grows its membership, its activities, and its geographic spread, it is rapidly becoming a leading authority and organization for women in the life sciences. Their focuses are on education, mentoring and networking, and on creating opportunities for leadership that can help advance careers. In the past WIB has been an incredible addition to the RESI conferences, sending esteemed life science women entrepreneurs to connect with investors specific to their indication. We look forward to working with them back again at future RESI conferences.

If your Tech Hub is looking for ways to add value to fundraising constituents, connect with the LSN business development team to see which offerings best fit your needs and the companies in your community. LSN shares the mission of global Tech Hubs in seeing promising technologies advance from the lab to the clinic, and into the hands of providers and their patients.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA) West Coast (USA) East Coast (USA) Midwest (USA) & Canada
Greg Mannix
Vice President International Business Development
Book a Meeting!		 Candice He
 Global Investment Strategist
Book a Meeting!		 Elizabeth Murphy
Manager of Business Development
Book a Meeting!		 Antoinette Lowre
Manager of Business Development
Book a Meeting!

Hot Investor Mandate: China-Focused VC Fund Invests Up to $25M, Most Interested in Therapeutics in Oncology and Metabolic Disorders

~ Next Phase Admin ~ Leave a comment

A sector-exclusive life sciences venture and growth equity fund focused on Asia has offices in USA, Hong Kong, and China. The firm is investing from its fifth fund closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. The firm focuses on China but also considers opportunities from USA.

In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Experienced Family Office Invests in USA-Based Therapeutics and Medical Device Companies, Can Invest Up to $30M

~ Next Phase Admin ~ Leave a comment

A family office with over 30 years of investment experience invests in many different sectors including early-stage biotech companies. The firm is based on a network of high-net worth individuals who invest in companies that identify to be of interest. Size of investment can largely vary based on the stage of the company; the firm has invested up to $30M, but initial investments typically range between $5-10M. The firm only considers USA-based opportunities.

The firm is interested in therapeutics and medical device companies, but will not invest in diagnostics or healthcare IT. The firm has several medical device and drug development companies in their portfolio and has no specific preference in terms of stage of development or indication.

The firm seek to work with experienced management teams with strong expertise in their field. The firm usually does not take a board seat or lead financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Capital Arm of a Large Company Invests in Medical Devices, Diagnostics, Digital Health, and Life Science Tools in Underserved Geographies

~ Next Phase Admin ~ Leave a comment

A venture and expansion capital arm of a large company is currently seeking new opportunities in the life science space. The firm’s initial equity investments range from $5-15M, and increase up to $20M total through subsequent rounds.

The firm is currently most interested in the following Healthcare subsectors: Analytics & Interoperability, Diagnostic Tools, Digital Health, Medical Devices, Pharma Services/IT, and Research Tools.

The firm generally invests in Series B rounds, with some flexibility to go earlier or later in stage. The firm typically looks for companies with up to $10 million of trailing revenue, 50%+ annual growth rate, and visionary management teams with entrepreneurial mindsets. The firm is particularly interested in companies located in underserved geographies with an emphasis on the mid-country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Strategic Healthcare Venture Arm Seeks New Investment Opportunities in Medical Devices, Diagnostics, Digital Health

~ Next Phase Admin ~ Leave a comment

A strategic healthcare venture investment subsidiary makes equity investments into early- to late-stage companies of approximately $3 million to $10 million initially, with additional capital reserved for follow on financings. It generally invests $4 million to $15 million in a company over the life cycle. The firm only invests in companies that are based in the US.

The firm is currently looking for new opportunities in the Medical Device, Diagnostic, Healthcare IT and Healthcare Services spaces. The firm considers all classes of medical devices and focuses on device companies in the pre-commercial stage. In terms of diagnostics, the firm has a preference for platform technologies and companies whose products are already commercialized. The firm’s Healthcare IT and Healthcare Services investments are typically in the commercial or growth stages.

The firm invests in privately held healthcare companies. The firm looks to invest in companies with a strong management team who can demonstrate relevant experience, depth and capability to build and scale the business and attract customers. The firm typically requests a Board seat or Board observation rights for each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot AI Mandate: VC Invests in Digital Health in North America & Asia

~ Next Phase Admin ~ Leave a comment

A venture capital firm founded in 1996 with offices in Silicon Valley, Beijing, Shanghai, and Tokyo has over $4.2B assets under management and has invested in over 400 companies. In 2019, the firm closed Fund IX at $780M, its largest fund to date. The firm invests mainly in early-stage technology companies (i.e. internet, SaaS, consumer-tech, etc.) with high disruptive potential and seeks to be the first institutional investor, but dedicates a small amount of capital (about 20% of the fund) to later-stage companies as well. Typically, first checks fall in the $2-5M range in Seed to Series A rounds, but the firm has made investments as small as $250K. Overall, the firm invests in over 20 companies per year across North America and Asia. In terms of healthtech specifically, the firm aims to make at least 1-2.

The firm is mainly interested in digital health opportunities and will not consider therapeutics or medical devices. The firm will stray away from anything that involves FDA regulatory approval. Previous investments of the firm include a Google Glass-powered remote scribe platform that improves the workflow of physicians, an AI engine that matches cancer patients with clinical trials, a wearable health tracker for healthy lifestyle management, etc. Companies do not need to be generating revenue prior to investment.

The firm invests in private companies with strong technology and can work with different kinds of management teams that are ideally devoted full-time to the company. The firm will almost always act as the lead investor and seek board representation, staying actively involved in their portfolio companies. The firm prefers to have a syndicate of co-investors invest alongside the firm, but this is not an absolute requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.